← Leaderboards
Eric R. Fearon
University Of Michigan At Ann Arbor
$27,558,344
Attributed
$27,558,344
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $11M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$99,941,679 · 17
By mechanism
P30$92,089,828 · 10
R01$6,548,356 · 2
P50$894,031 · 2
R56$305,550 · 1
U19$103,708 · 1
M01$206 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Max S. Wicha$49,028,071
- Theodore S Lawrence$30,022,406
- Weiping Zou$38,970,401
- Shaomeng Wang$36,139,079
- Marina Pasca Di Magliano$14,782,555
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProgramsFundingMemberInnovationMichiganCancer Center Support GrantUniversitiesLeadershipFosteringCancer BurdenUniversity Of Michigan Comprehensive Cancer CenterClinical ResearchInterdisciplinary CollaborationResource SharingCollaborationsCaringResearch PersonnelPreventionEarly DiagnosisCancer CenterCatchment AreaMissionPublications
Grant awards (117)
University of Michigan Rogel Cancer Center Support Grant 2023-2028$7,155,482
P30 · FY2025 · CA · contact PI
Leadership Planning and Evaluation$706,824
P30 · FY2025 · CA · contact PI
Cancer Center Administration$700,429
P30 · FY2025 · CA · contact PI
Developmental Funds$582,618
P30 · FY2025 · CA · contact PI
Community Outreach and Engagement$430,932
P30 · FY2025 · CA · contact PI
University of Michigan Rogel Cancer Center Support Grant 2023-2028$195,000
P30 · FY2025 · CA · contact PI
Developmental Research Program$147,908
P50 · FY2025 · CA · contact PI
Administrative Supplement P30 Cancer Center Support Grant (CCSG): Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy$125,000
P30 · FY2025 · CA · contact PI
University of Michigan Rogel Cancer Center Support Grant 2023-2028$7,194,632
P30 · FY2024 · CA · contact PI
Leadership Planning and Evaluation$679,864
P30 · FY2024 · CA · contact PI
Cancer Center Administration$673,711
P30 · FY2024 · CA · contact PI
Developmental Funds$560,394
P30 · FY2024 · CA · contact PI
Supplement to Enhance the Utility of Data Available through the Childhood Cancer Data Initiative (CCDI) Ecosystem$500,000
P30 · FY2024 · CA · contact PI
University of Michigan Rogel Cancer Center Support Grant 2023-2028$195,000
P30 · FY2024 · CA · contact PI
Discovery of circulating tumor RNA biomarkers for pancreatic cancer detection and monitoring$195,000
P30 · FY2024 · CA · contact PI
Developmental Research Program$141,991
P50 · FY2024 · CA · contact PI
University of Michigan Rogel Cancer Center Support Grant 2023-2028$7,339,791
P30 · FY2023 · CA · contact PI
Leadership Planning and Evaluation$694,687
P30 · FY2023 · CA · contact PI
Cancer Center Administration$688,399
P30 · FY2023 · CA · contact PI
Developmental Funds$572,612
P30 · FY2023 · CA · contact PI
Administrative Supplements for the NCI P30 Cancer Center Support Grants for Multi-Channel Communication Campaigns for Improvements in Cancer Education and Outcomes (MICEO) in Underserved Populations$199,992
P30 · FY2023 · CA · contact PI
Developmental Research Program$150,752
P50 · FY2023 · CA · contact PI
Cancer Center Support Grant 2018-2023$6,562,534
P30 · FY2022 · CA · contact PI
Developmental Funds$971,861
P30 · FY2022 · CA · contact PI
Cancer Center Administration$777,536
P30 · FY2022 · CA · contact PI
Leadership Planning and Evaluation$555,300
P30 · FY2022 · CA · contact PI
Cancer Center Support Grant 2018-2023$6,684,803
P30 · FY2021 · CA · contact PI
Developmental Funds$989,968
P30 · FY2021 · CA · contact PI
Cancer Center Administration$792,023
P30 · FY2021 · CA · contact PI
Leadership Planning and Evaluation$565,645
P30 · FY2021 · CA · contact PI
Development of a Standardized Electronic Treatment Plan Builds for NCI-supported Clinical Trials Year 2$300,000
P30 · FY2021 · CA · contact PI
Experimental Therapeutics Clinical Trials Network$35,000
P30 · FY2021 · CA · contact PI
Cancer Center Support Grant 2018-2023$6,684,803
P30 · FY2020 · CA · contact PI
Developmental Funds$989,968
P30 · FY2020 · CA · contact PI
Cancer Center Administration$792,023
P30 · FY2020 · CA · contact PI
Leadership Planning and Evaluation$565,645
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$500,000
P30 · FY2020 · CA · contact PI
Targeting TMPRSS2 expression as a therapy for coronavirus infection and replication$390,000
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$300,000
P30 · FY2020 · CA · contact PI
Development of a Standardized Electronic Treatment Plan Builds for NCI-supported Clinical Trials$294,573
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$200,000
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$150,000
P30 · FY2020 · CA · contact PI
Support of Collaborations with the ETCTN through the EDDOP$67,470
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$60,000
P30 · FY2020 · CA · contact PI
Cancer Center Support Grant 2018-2023$6,684,803
P30 · FY2019 · CA · contact PI
Developmental Funds$989,966
P30 · FY2019 · CA · contact PI
Cancer Center Administration$792,025
P30 · FY2019 · CA · contact PI
Leadership Planning and Evaluation$565,643
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant 2018-2023$246,238
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant 2018-2023$60,000
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant 2018-2023$50,000
P30 · FY2019 · CA · contact PI
Cancer Center Support Grant 2018-2023$6,681,232
P30 · FY2018 · CA · contact PI
Developmental Funds$989,439
P30 · FY2018 · CA · contact PI
Cancer Center Administration$791,601
P30 · FY2018 · CA · contact PI
Leadership Planning and Evaluation$565,343
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant 2018-2023$249,249
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant 2018-2023$224,298
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant 2018-2023$191,554
P30 · FY2018 · CA · contact PI
Integrating an Open Repository of Polygenic Risk Scores for Major Cancer Sites with a Visual Catalog$149,955
P30 · FY2018 · CA · contact PI
Cancer Center Support Grant 2018-2023$60,000
P30 · FY2018 · CA · contact PI
Cancer Center Administration$9,970
P30 · FY2018 · CA · contact PI
Developmental Funds$9,970
P30 · FY2018 · CA · contact PI
Leadership Planning and Evaluation$9,970
P30 · FY2018 · CA · contact PI
Cancer Center Administration$8,973
P30 · FY2018 · CA · contact PI
Leadership Planning and Evaluation$8,971
P30 · FY2018 · CA · contact PI
Developmental Funds$8,971
P30 · FY2018 · CA · contact PI
Cancer Center Administration$7,663
P30 · FY2018 · CA · contact PI
Leadership Planning and Evaluation$7,661
P30 · FY2018 · CA · contact PI
Developmental Funds$7,661
P30 · FY2018 · CA · contact PI
Cancer Center Administration$2,401
P30 · FY2018 · CA · contact PI
Developmental Funds$2,399
P30 · FY2018 · CA · contact PI
Leadership Planning and Evaluation$2,399
P30 · FY2018 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$6,166,044
P30 · FY2017 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$50,000
P30 · FY2017 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$30,973
P30 · FY2017 · CA · contact PI
University of Michigan Comprehensive Cancer Center Support Grant$6,209,909
P30 · FY2016 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$271,250
R01 · FY2015 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$263,112
R01 · FY2014 · CA · contact PI
Development Research Program$63,791
P50 · FY2014 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$254,975
R01 · FY2013 · CA · contact PI
Development Research Program$145,111
P50 · FY2013 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$271,250
R01 · FY2012 · CA · contact PI
Development Research Program$81,896
P50 · FY2012 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$271,250
R01 · FY2011 · CA · contact PI
Development Research Program$81,402
P50 · FY2011 · CA · contact PI
PROGRAM LEADERS$448,297
P30 · FY2010 · CA · contact PI
Development Research Program$81,180
P50 · FY2010 · CA · contact PI
PROGRAM LEADERS$445,434
P30 · FY2009 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$305,550
R56 · FY2009 · CA · contact PI
The Role of Beta-catenin/Tcf Pathway Defects in Cancer$267,255
R01 · FY2009 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$280,202
R01 · FY2008 · CA · contact PI
The Role of Beta-catenin/Tcf Pathway Defects in Cancer$267,255
R01 · FY2008 · CA · contact PI
PROGRAM LEADERS$247,099
P30 · FY2008 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$280,202
R01 · FY2007 · CA · contact PI
The Role of Beta-catenin/Tcf Pathway Defects in Cancer$267,255
R01 · FY2007 · CA · contact PI
PROGRAM LEADERS$247,099
P30 · FY2007 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$288,570
R01 · FY2006 · CA · contact PI
The Role of Beta-catenin/Tcf Pathway Defects in Cancer$275,237
R01 · FY2006 · CA · contact PI
PROGRAM LEADERS$247,099
P30 · FY2006 · CA · contact PI
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$295,515
R01 · FY2005 · CA
The Role of Beta-catenin/Tcf Pathway Defects in Cancer$283,603
R01 · FY2005 · CA
CDX2 Tumor Suppressor Pathway Defects in Colon Cancer$295,515
R01 · FY2004 · CA
ROLE OF BETA CATENIN/TCF PATHWAY DEFECTS IN CANCER$267,210
R01 · FY2004 · CA
CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCER$278,263
R01 · FY2003 · CA
ROLE OF BETA CATENIN/TCF PATHWAY DEFECTS IN CANCER$267,210
R01 · FY2003 · CA
CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCER$272,442
R01 · FY2002 · CA
ROLE OF BETA CATENIN/TCF PATHWAY DEFECTS IN CANCER$267,210
R01 · FY2002 · CA
PILOT--CANCER GENETICS AND VIROLOGY$0
P30 · FY2002 · CA
COLON TUMOR PROJECT$0
U19 · FY2002 · CA
ROLE OF BETA CATENIN/TCF PATHWAY DEFECTS IN CANCER$267,282
R01 · FY2001 · CA
CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCER$266,718
R01 · FY2001 · CA
PILOT--CANCER GENETICS AND VIROLOGY$0
P30 · FY2001 · CA
COLON TUMOR PROJECT$0
U19 · FY2001 · CA
ROLE OF BETA CATENIN/TCF PATHWAY DEFECTS IN CANCER$268,136
R01 · FY2000 · CA
CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCER$261,439
R01 · FY2000 · CA
COLON TUMOR PROJECT$103,708
U19 · FY2000 · CA
FUNCTIONAL STUDIES OF THE DCC TUMOR SUPPRESSOR GENE$206
M01 · FY2000 · RR